Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- BLUETTI Apex 300 Portable Power Station Hits Retail Markets
- Significant Market Impacts from Tariffs in Asia-Pac Region
- How Big Tech's AI Investment is Shaping the Future
- Viridien’s Voting Rights and Shareholder Information Update
- Clarifying the Status of the Great Sea Interconnector Project
- Chevron's Q2 Earnings Predictions and Market Insights Explored
- WSPN Unveils Global Payment 1.0 for Institutional Crypto Needs
- Oculis Enhances Financial Flexibility with Expanded Loan Facility
- Oculis Enhances Financial Flexibility with New Loan Structure
- Oculis Expands Loan Facility for Advanced Biopharmaceutical Development
- The9 and YGG Team Up for Revolutionary Gaming Platform
- Exxon Mobil's Q2 Earnings Expectations and Analyst Insights
- Oceanco Welcomes Gabe Newell as New Shareholder for Growth
- A Vibrant Tribute to Elvis at Westgate Las Vegas Resort
- The9 and YGG Team Up for Revolutionary Web3 Gaming Hub
- Medit i900 Mobility Launch: Transforming Dental Practices
- Oceanco Enters New Era with Gabe Newell at the Helm
- SciBase Successfully Completes Directed Share Issue with Castle Biosciences
- Energenesis Biomedical's ENERGI-F705PD Shows Promise for Parkinson's Disease
- Recent Changes in Shareholder Holdings at TCM Group A/S
- Trump Demands Pharmaceutical Price Cuts: A 60-Day Challenge
- Zeekr Group Reports Impressive Vehicle Deliveries for July
- Stock Market Dynamics Shift as Focus Turns to Employment Trends
- Man Group's Strategic Position in American Axle Transactions
- Coinbase Reports Strong Profit Yet Faces After-Hours Decline
- AI-Driven Trading Strategy Outshines Market Benchmarks Significantly
- Groundbreaking Data Center Development in Tokyo's Fuchu Park
- Exciting Developments in Hyperscale Data Centers in Tokyo
- Statkraft Divests Enerfín's Canadian Operations to Atlantica
- Yutong Van Achieves Exceptional Performance in Challenging Areas
- Celebrating Youth Creativity: Planet Classroom's Impactful Films
- Zoe Energy Achieves Prestigious Tier 1 Status in Energy Storage
- Danish Aerospace Company's New Innovation in Space Imaging
- First Mold's Innovative Injection Solutions Set for Meximold 2025
- Transformative Leadership Changes at Capgemini Reflect Future Vision
- Air France-KLM Launches New Liquidity Contract for Shares
- Capgemini Leadership Change: William Rozé Steps Down from Role
- Air France-KLM Launches New Liquidity Contract with Rothschild
- Pawan Dhir Expands Stake in NB Private Equity Partners Ltd
- Bekaert's Strategic Liquidity Agreement and Share Buyback Update
- Borregaard ASA Welcomes New Leadership for Future Growth
- Key Insights on Total Voting Rights for Octopus Titan VCT
- Ress Life Investments A/S Announces Latest Net Asset Value
- Youth Collaboration Strengthens US-China Cultural Ties
- Understanding Total Voting Rights and Capital Increases
- Understanding Voting Rights and Capital for Investors Today
- Understanding Total Voting Rights and Share Capital Structure
- Octopus Apollo VCT plc Voting Rights Update and Insights
- Tallinna Vesi Sees Growth in Second Quarter Sales Results
- Understanding PayPoint Plc's Latest Voting Rights Update